A longitudinal study of human papillomavirus 16 L1, E6, and E7 seropositivity and oral human papillomavirus 16 infection

Sexually Transmitted Diseases

Volumn 42, Issue 2, 2015, Pages 93-97

  Beachler, Daniel C ^a   Viscidi, Raphael ^b   Sugar, Elizabeth A ^a   Minkoff, Howard ^c   Strickler, Howard D ^d   Cranston, Ross D ^e   Wiley, Dorothy J ^f   Jacobson, Lisa P ^a   Weber, Kathleen M ^a   Margolick, Joseph B ^b   Reddy, Susheel ^g   Gillison, Maura L ^h   D'Souza, Gypsyamber ^a,i  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b And Immunology   (United States)

^c MAIMONIDES MEDICAL CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Jr Hospital of Cook County   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

L1 CAPSID; PROTEIN E6; PROTEIN E7; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS DNA; VIRUS PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; INFECTION RISK; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NONHUMAN; ORAL SEX; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; SEROPREVALENCE; SMOKING; VIRUS CAPSID; ANUS NEOPLASMS; CASE CONTROL STUDY; CLINICAL TRIAL; COMPLICATION; ISOLATION AND PURIFICATION; MULTICENTER STUDY; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UTERINE CERVICAL NEOPLASMS;

ADULT; ANUS NEOPLASMS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84921914386     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000236     Document Type: Conference Paper

References (31)

1. Beachler DC, Weber KM, Margolick JB, et al. Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev 2012; 21:122-133.
2. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the united states, 2009-2010. JAMA 2012; 307:693-703.
3. Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14:467-475.
4. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and-18infections. J Natl Cancer Inst 2010; 102:1653-62.
5. Wilson L, Pawlita M, Castle PE, et al. Seroprevalence of 8 oncogenic human papillomaviruses and acquired immunity against re-infection. J Infect Dis 2014; 210:448-455.
6. Castellsague X, Naud P, Chow S, et al. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally-acquired HPV-16/18 antibodies: Analysis of the control arm of PATRICIA. J Infect Dis 2014; 210:517-534.
7. Malik ZA, Hailpern SM, Burk RD. Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. Viral Immunol 2009; 22:445-449.
8. Wentzensen N, Rodriguez AC, Viscidi R, et al. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the guanacaste natural history study. J Infect Dis 2011; 204:94-102.
9. Viscidi RP, Snyder B, Cu-Uvin S, et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 2005; 14:283-288.
10. Palmroth J, Namujju P, Simen-Kapeu A, et al. Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. Scand J Infect Dis 2010; 42:379-384.
11. Lehtinen M, Pawlita M, Zumbach K, et al. Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. Am J Obstet Gynecol 2003; 188:49-55.
12. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-56.
13. Kreimer AR, Johansson M, Waterboer T, et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 2013; 31:2708-2715.
14. Kaslow RA, Ostrow DG, Detels R, et al. The multicenter AIDS cohort study: Rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126:310-318.
15. Barkan SE, Melnick SL, Preston-Martin S, et al. The women's interagency HIV study. WIHS Collaborative Study Group. Epidemiology 1998; 9:117-125.
16. Viscidi RP, Ahdieh-Grant L, Clayman B, et al. Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis 2003; 187:194-205.
17. Wang SS, Schiffman M, Shields TS, et al. Seroprevalence of human papillomavirus-16,-18,-31, and-45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003; 89:1248-1254.
18. Sehr P, Zumbach K, Pawlita M. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: Validation for HPV serology. J Immunol Methods 2001; 253:153-162.
19. Broutian TR, He X, Gillison ML. Automated high throughput DNA isolation for detection of human papillomavirus in oral rinse samples. J Clin Virol 2011; 50:270-275.
20. Beachler DC, Sugar EA, Margolick JB, et al. Risk factors for oral HPV infection acquisition and clearance among HIV-infected and HIV-uninfected adults. Am J Epidemiol 2014.
21. Franceschi S, Baussano I. Naturally-acquired immunity against HPV: Why it matters in the HPV vaccine era. J Infect Dis 2014; 210: 507-509.
22. Lu B, Viscidi RP,Wu Y, et al. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res 2012; 72:676-685.
23. Mooij SH, Landen O, van der Klis FR, et al. No evidence for a protective effect of naturally induced HPVantibodies on subsequent anogenital HPV infection in HIV-negative and HIV-infected MSM. J Infect 2014; 69:375-86.
24. Beachler DC, D'Souza G, Sugar EA, et al. Natural history of anal versus oral HPV infection in HIV-infected men and women. J Infect Dis 2013; 208:330-9.
25. Gravitt PE. Evidence and impact of human papillomavirus latency. Open Virol J 2012; 6:198-203.
26. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica vaccine trial. Cancer Prev Res (Phila) 2013; 6:1242-1250.
27. Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in costa rica. PLoS One 2013; 8:e68329.
28. Wilson LE, Pawlita M, Castle PE, et al. Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL triage study. Int J Cancer 2013; 132:2172-2181.
29. Kreimer AR, Alberg AJ, Viscidi R, et al. Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16,-18, and-33 seroprevalence. Sex Transm Dis 2004; 31:247-256.
30. Lin SW, Ghosh A, Porras C, et al. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: Comparison of serological assays. PLoS One 2013; 8:e53067.
31. Kreimer AR, Johansson M, Hildesheim A, et al. Reply to P.E. castle. J Clin Oncol 2013; 32:361-362.